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Abstract
THE EFFECT OF E-CADHERIN LOSS ON MELANOMA FORMATION AND
METASTASIS.
Lara E. Rosenbaum, William Damsky, Katrina Meeth, and Marcus
Bosenberg. Department of Dermatology, Yale University School of
Medicine, New Haven, CT.

Melanoma is the most lethal form of skin cancer and accounts for the
majority of skin cancer related mortality. Early metastases are
characteristic of melanoma and are an ominous sign, as current
therapeutic interventions have little effect on overall survival. The lack of
accurate prognostic indicators and effective therapies emphasize the
need for a better understanding of the genetic and phenotypic changes
in melanoma formation and progression. One such change is the loss of
E-cadherin, which normally plays a role in cell-cell adhesion and is thought
to be a central feature of epithelial-mesenchymal transition (EMT).
Maintenance of E-cadherin in melanoma may function to restrict
melanoma invasion, and loss of E-cadherin expression is associated with
mesenchymal features and melanoma metastasis. While several studies
have suggested that loss of E-cadherin is associated with cancer
progression, functional evaluation of the effects of E-cadherin loss on
metastasis has not been well established.
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In order to evaluate these important issues on the role of E-cadherin in
melanoma formation and metastasis, we have utilized a wellcharacterized conditional mouse model combining the activating Braf
V600E mutation with Pten tumor suppressor loss (Braf/Pten tumor model).
This model allows us to alter these genes in mouse melanocytes in a
spatially and temporally restricted manner, producing melanoma
specifically and reproducibly. We have combined this model with
conditional E-cadherin inactivation in order to evaluate the role of Ecadherin loss on melanoma formation, progression and metastasis as well
as changes in cell morphology and signaling. Loss of E-cadherin
significantly decreases survival of mice in the Braf/Pten tumor model
(p=0.024) and alters the expression of markers of EMT as demonstrated by
RNA microarray analysis. Surprisingly, no difference in metastases to either
the lymph nodes (p=0.28) or lungs (p=0.39) are seen with loss of Ecadherin.

Additionally, Braf activation in combination with E-cadherin loss
(Braf/Ecad model) leads to melanoma in 100% of mice with tumor death
occurring after an average of 302 days (range: 199 – 395 days) or
approximately 10 months. This novel model is in striking contrast to the
Braf/Pten tumor model, which has an average lifespan of 40 days. No
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tumors develop in mice with Braf activation alone or E-cadherin loss alone
nor in mice with both loss of E-cadherin and loss of Pten. The Braf/Ecad
tumor model shows activation of mammalian target of rapamycin (mTOR)
signaling, a commonly dysregulated protein in human cancers, as well as
activity in the P13K/Akt pathway which regulates cellular proliferation and
survival. Some markers of EMT are also upregulated in the Braf/Ecad
tumor model.

These findings functionally delineate the role of E-cadherin loss in
melanoma formation, metastasis and EMT. Additional evidence is
garnered which supports the role of E-cadherin as a tumor suppressor
gene and that its loss is functionally important in altering key pathways of
cellular growth and survival. With better understanding of melanoma,
new treatments will be developed to help manage this devastating
cancer.
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Introduction
MELANOMA
Importance of Melanoma
Melanoma is a common cancer arising from melanocytes, the pigmentforming cells of the skin. Given its aggressive nature and increasing
incidence, research to further understand melanoma formation and
metastasis is important for improving human health. It is estimated that
76,250 cases of melanoma and 9,180 deaths due to melanoma will occur
in 2012, making it the fifth and sixth most common cancer diagnosed in
men and women, respectively (1). In fact, 1 in 36 men and 1 in 55 women
will develop melanoma during the course of a lifetime (1). Unfortunately,
as the incidence rate is increasing by >2% per year in the white
population, melanoma continues to be of significant concern (2).

If melanoma is recognized and diagnosed early, treatment may involve
simple local excision with greater than 90% survival at 10 years for patients
with melanomas less than 1.00 mm thick (3). However, once melanoma
has metastasized, it is challenging to treat and prognosis is poor. At best,
one-year survival in this group is 62% (based on location of melanoma
spread); at worst, one-year survival can be as low as 33% (3). Despite the
increasing incidence of melanoma, the death rate due to melanoma has
remained essentially stable over the last 20 years (4).
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Therapeutic Advances
Recent advances in immunomodulatory therapies and targeted therapies
has led to Food and Drug Administration (FDA) approval of two new
treatments for melanoma in 2011. These novel therapies are the first to be
approved for melanoma treatment in the last 13 years.

The first, ipilimumab, is a monoclonal antibody that blocks cytotoxic Tlymphocyte-associated antigen 4 (CTLA-4). Blocking of CTLA-4 leads to
enhancement of antitumor activity. While survival continues to be poor in
patients with metastatic melanoma, treatment with ipilimumab can lead
to prolonged survival in approximately 20% of patients (compared to
<10% without ipilimumab) (5) (6).

The second new treatment is vemurafenib (also known as PLX4032), a
small molecule inhibitor of mutant Braf. Braf, an intracellular protein
important in pathways affecting cell division, is mutated in approximately
50% of human melanomas (7) (see next section: Melanoma Genetics). In
patients treated with vemurafenib, there is a 6-month survival of 84%,
compared to 64% at 6 months in patients treated with dacarbazine (a
standard chemotherapeutic agent) (7). Though both of these therapies
show exceptional promise and are making a clear impact on patient
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lives, more work is needed to both better understand and treat this lethal
disease.

Melanoma Genetics
Much work has been completed in recent years to assess commonly
mutated genes in melanoma with the hopes of better understanding this
deadly disease and developing improved therapeutics. As discussed
above (see previous section: Therapeutic advances), Braf is mutated in
about 50% of human melanomas (7) leading to constitutive activation of
the mitogen activated protein kinase (MAPK) pathway. Activation of this
pathway leads to increased cellular proliferation. Confirmation of mutant
Braf as an activating oncogenic mutation has been confirmed in several
studies, including in a mouse model developed by the Bosenberg lab (8).

Also commonly deregulated in melanoma are proteins in the
phosphoinositide 3-kinase (PI3K) / Akt pathway, which also regulates
cellular proliferation and survival. Within this pathway is the phosphatase
and tensin homologue (Pten), which inhibits activation of the PI3K/Akt
pathway. Inversely, loss of the tumor suppressor Pten leads to activation
of the pathway. Unlike Braf, Pten is only mutated in approximately 5% of
melanomas; however, expression is lost in up to 50% of melanomas (9)
(10). Like Braf, this mutation has been shown to be functionally important
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in melanoma formation and progression by the Bosenberg lab (8).
Additionally, activation of the PI3K/Akt pathway leads to activation of
mammalian target of rapamycin (mTOR) signaling, which consists of two
protein complexes, mTOR complex 1 (mTORC1) and mTOR complex 2
(mTORC2). mTOR signaling is important for a myriad of processes related
to cellular metabolism and is commonly dysregulated in cancer (11).

E-CADHERIN
E-cadherin Function
E-cadherin is a cell-cell adhesion protein that is part of a family of proteins
called cadherins. The classic cadherins, which includes E-cadherin, are
calcium-dependent homophilic molecules that can be found throughout
the human body (12). E-cadherin was named due to its predominance in
epithelial tissues in which it forms the adherens junction. It is expressed on
keratinocytes as well as melanocytes and is functionally important in the
interaction of these cells (13). Other cadherins include N-cadherin (neural
cadherin), P-cadherin (placental cadherin) and R-cadherin (retinal
cadherin), though many other classical cadherins have also been
identified.

E-cadherin is a single pass transmembrane protein. The extracellular
domain consists of five cadherin-type repeats that in conjunction with
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calcium form a rod-like structure. The 3-D configuration of these
extracellular domains within an adhesive cell-cell homophilic bond
remains unclear, though several models have been proposed (12). The
intracellular interactions and functions of E-cadherin have also been well
studied. E-cadherin is attached to the actin cytoskeleton through an
interaction with α-catenin and β-catenin. Additional proteins (p120,
formin-1, vinculin and α-actinin) also interact with E-cadherin intracellularly
and may play a role in actin-binding or other cell-signaling functions (12).

Importance of E-cadherin in Cancer Biology
Germline mutations in E-cadherin lead to hereditary diffuse gastric cancer
(HDGC), an autosomal dominant cancer syndrome. In patients with Ecadherin mutations, >80% will develop advanced gastric cancer by 80
years of age; thus, prophylactic gastrectomy is typically offered at age 20
when the risk of cancer development is still quite low (14). While no
dominant mutation has been identified in CDH1 (the gene for E-cadherin),
over 100 mutations have been identified in unrelated families of varying
countries of origin (15). Diffuse gastric cancer begins to develop in these
patients when the second (normal) copy of E-cadherin is either
inactivated, dowregulated (often through promoter hypermethylation) or
lost (15), suggesting a role for E-cadherin as a tumor suppressor (see next
section: E-cadherin as Tumor Suppressor). Additionally, women with this
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mutation have a significantly increased risk of developing lobular breast
cancer (60% by age 80) and screening for breast cancer typically begins
by age 35 (14).

Apart from HDGC, E-cadherin is also lost or downregulated in numerous
human cancers in individuals with normal E-cadherin in the rest of their
tissues. E-cadherin has shown to be downregulated in many cancers,
including head and neck squamous cell carcinomas, lobular breast
carcinoma, colorectal carcinoma, gastric carcinomas, prostate
carcinoma, lung carcinoma, thyroid carcinoma, hepatocellular
carcinoma, bladder carcinoma, and melanoma (16), (17). While for
many of these cancers, it is thought that loss of E-cadherin leads to a
poorer prognosis (compared to intact E-cadherin expression), this
relationship has sometimes been difficult to conclusively establish in many
of these cancers, including in melanoma (17).

E-cadherin as Tumor Suppressor: Activation of the PI3K/Akt Pathway
As discussed in the previous section, one of the strongest suggestions that
E-cadherin functions as a tumor suppressor is the discovery that germline
mutations lead to an autosomal dominant cancer syndrome. Indirectly,
loss of E-cadherin, either through mutations, loss of heterozygosity, or
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hypermethylation, is noted in many human cancers, implicating a key role
in cancer development (18).

Many recent studies have utilized cancer cell lines to demonstrate a
relationship between loss of E-cadherin and activation of the PI3/Akt
pathway (19) (20) (21). In Lau et al., the authors used ovarian cancer cell
lines and were able to show that loss of E-cadherin leads to
phosphorylation (and thus activation) of Akt as well as increased cellular
growth. They showed some evidence that this activation was due to βcatenin inhibiting early growth response gene 1 (Egr1), which in turn
downregulated Pten (19).

Not all studies have implicated β-catenin as the key mediator of Pten
downregulation by E-cadherin. In Li et al., researchers used breast
carcinoma cell lines to investigate the relationship between E-cadherin
and Pten. They were able to show that both loss of E-cadherin and
disruption of E-cadherin cell-cell adhesion leads to decreased levels of
intracellular Pten (21). These findings suggest that activation of the
PI3K/Akt pathway due to loss of E-cadherin is not due exclusively to βcatenin.
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Finally, Fournier et al. were able to show that loss of E-cadherin activated
the PI3K/Akt pathway in normal breast epithelial cell lines also via
downregulation of Pten. By treating these cell lines with an E-cadherin
blocking antibody, these researchers were able to show an approximately
30% decrease in intracellular Pten. This finding correlated with increased,
disorganized cell growth (20).

EPITHELIAL-MESENCHYMAL TRANSITION (EMT)
History of EMT
In order to understand EMT, it is important to first understand the tissue
types being discussed. An epithelium consists of cells with apical-basal
polarity, strong cell-cell contacts, low motile capacity and which typically
perform a secretory or barrier role. Mesenchymal cells, on the other hand,
have front-back polarity or no polarity, are spindle-shaped, have few cellcell contacts, are highly motile and may perform scaffolding or anchoring
roles (22), (23). The concept of EMT was first described by RL Trelstad, JP
Revel and ED Hay in 1966 while investigating chick embryogenesis to
explain the formation of mesoderm (mesenchymal tissue) from ectoderm
(an epithelium) in the embryo (24) (25). EMT occurs most clearly during
gastrulation and neural crest cell formation. In gastrulation, some cells of
the ectoderm begin to ingress and take on more mesenchymal features,
eventually becoming the mesoderm (23). Further in embryogenesis, the
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neural tube will form and begin to close. At the time of closing or just
after, cells from the neural ectoderm undergo an EMT to form neural crest
cells (26). Neural crest cells give rise to many cell types in the complete
embryo, including neurons, Schwann cells and melanocytes (26).

Expression of many proteins is altered during the course of an EMT in
embryogenesis. Studies have shown that E-cadherin, which is highly
expressed in epithelial tissues, is lost and N-cadherin is upregulated (26).
This phenomenon is frequently termed “cadherin switching.” Vimentin, a
cytoskeletal protein, and fibronectin, an extracellular glycoprotein, are
also upregulated (27), (28). Snail, Slug, Twist and Zeb1, transcription
factors that repress transcription of the gene for E-cadherin, are
upregulated (26), (27). Additional markers of EMT have also been
described (28).

EMT in Cancer Biology
The acquisition of mesenchymal traits by epithelial cancer cells during the
process of tumor invasion and metastasis has been a subject of intense
interest recently. This process has several features of epithelial
mesenchymal transitions (EMT) described in developmental biology
studies (29). Loss of E-cadherin expression and increased expression of
members of the Twist family of zinc finger transcription factors are key
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features of EMT. While several studies have demonstrated that expression
of mesenchymal markers is associated with progression of many cancers,
functional evaluation of the effects of altering the characteristic features
of EMT on metastasis has not been well established.

The majority of studies establishing the existence of EMT in cancer biology
have used in vitro assays (28). These assays have demonstrated changes
in cell morphology, a loss of cell polarization, increased cell matrix
interactions, increased motility, and resistance to anoikis (a form of
programmed cell death), which all suggest a loss of epithelial features
and a gain of mesenchymal cell characteristics. These assays suggest an
EMT has occurred and are consistent with acquisition of increased
invasive capabilities.

Despite clear in vitro evidence, the in vivo evidence for EMT has been
somewhat more controversial (30). On one hand, a xenograft study using
human cell lines in immunocompromised mice showed that loss of Ecadherin in immortalized human breast epithelial cells resulted in
increased mesenchymal features and a more invasive and metastatic
phenotype when subcutaneously injected into mice (31). Other studies in
mouse models have found that when metastases of cells expected to
have undergone EMT were analyzed, they resembled epithelial cells more
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than mesenchymal cells. This suggests that if an EMT had occurred it must
have been followed by a mesenchymal to epithelial cell transition (MET)
once the cells seeded the target organ (32). One hypothesis to explain
this phenomenon is that in the absence of a microenvironment inducing
EMT, the cells revert to their baseline epithelial state (33). Still other studies
have suggested that cells in vivo may actually exhibit a more hybrid
epithelial-mesenchymal phenotype compared to the more complete EMT
seen in vitro (28). As stated above, the most convincing evidence for EMT
has been established in an in vitro environment. This environment is highly
artificial, lacking the complex cell-cell interactions in a three-dimensional
space with no vascular, neurologic, or endocrine input. Additionally, if
EMT were so critical to cancer metastasis, one would expect this to be
readily apparent on histopathologic examination of human cancers sent
for diagnosis. This, however, is not typically seen, and in fact, most
invasive carcinomas are readily recognizable as of epithelial lineage (30).

Despite these controversies in the literature about EMT, many feel that Ecadherin loss is a central feature of EMT and is associated with cancer
progression (34). E-cadherin loss has also been documented in
melanoma and is frequently associated with increased N-cadherin
expression (35). Downregulation of E-cadherin in human melanoma may
occur by several mechanisms, including promoter hypermethylation (36),
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or repression by Snail, Slug, Zeb-1, or Tbx3 transcription factors (28). While
the correlation of E-cadherin downregulation in cancer has been
established, it is not clear how much of the EMT phenotype is due to Ecadherin loss and what the effect of E-cadherin loss is on metastasis.

A MOUSE MODEL OF MELANOMA
In order to address important questions in melanoma formation and
metastasis, a novel mouse model has been developed to investigate
specific genetic hits within the melanocytes of mice. These novel mouse
models are based on a transgenic mouse line that was previously
generated and characterized in which expression of a Cre recombinaseestrogen receptor fusion protein is expressed under the melanocytespecific tyrosinase promoter (Tyr::CreERT) (37). In brief, inducible
recombination of target genes containing lox sites that flank a DNA
sequence to be excised is efficiently induced by topical 4hydroxytamoxifen (4-HT) application in a spatially and temporally
restricted manner. Following the demonstration of functionality of the
Tyr::CreERT lines, lox knock-in lines of genes relevant to human melanoma
were acquired including Braf, Pten, and E-cadherin.

The Braf ser/thr kinase is the most commonly mutated gene known in
human melanoma, with about 60% of the most common forms of
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melanoma containing activating mutations of Braf (usually Braf V600E)
(38). Martin McMahon's laboratory at UCSF has generated a knock-in
allele of activated Braf (BrafCA) that is phenotypically wild type until Cremediated recombination produces an allele (Braf V600E) that contains
the V600E point mutation and retains a single intronic 34bp loxP site, but
otherwise resembles the wild type chromosome exactly (8).

The Pten tumor suppressor undergoes promoter hypermethylation and
reduction of expression in roughly 30% of melanomas, but is only mutated
in 5% of melanomas (10). We acquired a Pten allele from Ron DePinho
and James You in which exon 5 is flanked by lox sites (8).

E-cadherin is commonly downregulated in human melanoma with
variable levels of expression. While difficult to quantify, there is a trend
towards poorer prognosis in those melanomas with less expression of Ecadherin (17). The Bosenberg lab has acquired an E-cadherin allele with
lox sites that upon recombination leads to loss of exons 6 – 10 (39).

The Bosenberg lab has generated and analyzed 4-HT-treated cohorts of
the genetic hits individually and in many combinations. All of the
inductions of genetic recombination in these experiments were performed
with a relatively high concentration of topical 4-HT (50 mg/ml in DMSO)
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applied to the mouse on days 3, 5, and 7 of life and resulted in
generalized/systemic recombination of lox-containing alleles specifically
in melanocytes. Activation of Braf in melanocytes results in a mild
melanocytic hyperplasia/nevus formation (8), although tumor formation
has been noted using a similar mouse model (40). None of the other
individual genetic hits listed above have a clearly altered melanocytic
phenotype. In contrast, combinations of particular genetic hits have
produced some of the most interesting tumorigenic and metastatic
phenotypes described in any mouse model to date.

Activation of Braf combined with loss of Pten produces a dramatic
phenotype (Braf/Pten tumor model). Following induction of
recombination on days 3, 5, and 7 of life, widespread pigmented
melanocytic proliferations are evident within days; pups are uniformly
darkly pigmented within 12 days; nodular growths are evident within 15
days, and the mice need to be euthanized shortly after weaning (~30
days) secondary to decreased motility, failure to thrive, and the
observation of occasional death of littermates with similar behavioral
changes (8). All of the mice have multiple lymph node metastases, many
of which have shown evidence of growth within the lymph node with
partial to near-complete lymph node replacement. In addition, several
lung metastases are also typically noted within the two to three week
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span of this experiment (8). The Bosenberg lab has also optimized local
induction protocols in Tyr::CreERT Braf/Pten mice that result in melanoma
formation at the site of application that can be resected to allow for
longer follow-up of metastatic lesions (8).
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Statement of Purpose

Hypothesis
Loss of E-cadherin plays an important role in melanoma formation and
metastasis.

Specific Aim 1: Determine the role of E-cadherin in melanoma formation.
We will utilize the Tyr::CreERT mice that we generated and E-cadherinlox
mice (39) to conditionally inactivate E-cadherin following 4-HT-induced
Cre-mediated recombination. We will inactivate E-cadherin specifically in
melanocytes in both newborn and adult mice and evaluate effects on
melanocyte proliferation and survival at several time points (0, 3, 7, 21, 60,
and 360 days following recombination). 4-HT-treated Tyr::CreERT mice will
be used as controls for these experiments. We will determine if loss of Ecadherin in melanocytes is sufficient to induce melanoma by following a
cohort of 10 mice for 1 year that have undergone E-cadherin
recombination as newborns. These mice will be monitored daily for tumor
growth. Based on experience with other mouse models of melanoma, it is
likely that additional genetic hits will be required to determine if Ecadherin loss can contribute to melanoma formation. We will cross mice
to generate the following treated cohorts: E-cadherin loss with Braf
activation and E-cadherin loss with Pten loss.

26
Specific Aim 2: Determine the effect of E-cadherin loss on epithelialmesenchymal transition (EMT).
We will evaluate the effect of inactivation of E-cadherin on cellular
morphology, migration, and expression of markers of epithelialmesenchymal transition in vivo. E-cadherin has been proposed to be a
downstream effector in the process of EMT; however, a reciprocal
relationship has been demonstrated between E-cadherin re-expression in
melanoma cell lines and subsequent down regulation of N-cadherin (41).
We will examine whether loss of E-cadherin is sufficient to induce
additional markers of EMT. In particular, we will determine protein levels
on the skin tissues generated in Specific Aim 1 by western blotting of Ecadherin, N-cadherin, Vimentin, and Slug in lysates. In addition, we will
perform unbiased gene expression analyses (Affymetrix GeneChip Mouse
Gene 1.0 ST Arrays) in order to determine the gene set that is upregulated
and downregulated by inactivation of E-cadherin and specifically
examine markers associated with EMT.
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Specific Aim 3: Determine the effect of E-cadherin loss on melanoma
metastasis.
In order to determine the effect of E-cadherin on melanoma metastasis,
we will induce E-cadherin loss in the setting of Braf activation, Pten loss,
and Braf activation and Pten loss. These models have different
endogenous propensities for tumor formation and metastasis that may be
uniquely modified by E-cadherin loss. From previously published work by
the Bosenberg lab, we know that Braf activation with Pten loss results in
exuberant tumor formation without a clear latency and with bulky lymph
node metastases within weeks of induction. Isolated tumor cells are
present in the lung (8). We will carefully evaluate mice in these cohorts for
extent and character of metastatic disease and any alterations in these
phenotypes that E-cadherin loss causes. In addition to these "metastasis"
cohorts, we will carefully evaluate any mice for metastases from Specific
Aim 1 that form tumors following inactivation of E-cadherin and Braf
activation or inactivation of E-cadherin and Pten.

We will evaluate the histology of primary and metastatic melanomas
carefully to determine if there is an increase in the mesenchymal
characteristics of tumorigenic cells, including a more spindled
appearance, greater extent of invasion at the leading edge of the tumor,
and increases in local lymphovascular invasion. We expect that E-
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cadherin will alter the characteristics of both the primary melanomas and
metastases; however, it is unclear if the extent of metastasis will be altered
or if the sites will be altered.
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Methods

Work was completed by the following investigators:
Lara E. Rosenbaum (LER), William Damsky (WD), Katrina Meeth (KM)

Mouse strains and activation of Tyr-CreER
Responsible investigators: Breeding, genotyping and general
maintenance of the mouse colony was completed by WD and LER, with
WD being primarily responsible for the Braf E-cadherin cohort and Ecadherin cohort and LER primarily responsible for the Braf Pten, Pten Ecadherin and Braf Pten E-cadherin cohorts presented here.

The Tyr-CreER, Braf, Pten and E-cadherin mouse strains were genotyped
and assayed for recombination as previously described (37), (42), (43),
and (39). All strains were on a mixed background of C57BL/6, FVB and 129
mice. For tumor inductions, 4-hydroxytamoxifen (4-HT) (#H6278, 70% Zisomer from Sigma-Aldrich) was dissolved in dimethylsulfoxide (DMSO) to a
concentration of 50 mg/ml. For perinatal inductions, this 4-HT solution was
applied with a small paintbrush (enough to wet the skin) to the belly of the
mouse on postnatal days 3, 5 and 7. For localized tumor inductions, a
mouse was selected at postnatal day 21 and the hair between the
shoulder blades was removed with a topical depilatory. Next, 1 µl of 4-HT

30
at 8.3 mg/ml (dissolved in 1 part DMSO and 5 parts Ethanol) was directly
applied to the skin of the mouse in the hairless area. All experiments
involving animals were reviewed and approved by the Yale Institutional
Animal Care and Use Committee (IACUC).

Immunohistochemistry and western blotting
Responsible investigators: Immunohistochemistry was completed by KM.
Western blotting was completed by LER and KM.

Immunohistochemistry was performed on formalin-fixed, paraffinembedded tumor sections. Slides were processed using Vectastain
peroxidase kit (Vector, #PK-4000) and developed with a 3, 3’diaminobenzidine (DAB) substrate kit (Vector, #PK-4100), according to the
manufacturer’s instructions.

Western blotting was performed using standard methods on uncultured,
macrodissected tumor protein lysates.

The protein detection in the immunohistochemistry and western blotting
was accomplished with the following purchased antibodies:

From Cell Signaling Technology: phospho-4E-BP1 (Thr37/46) (#2855), Actin
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(#4970), Total Akt (#9272), phospho-Akt (Thr308) (#2965), phospho-Akt
(Thr450) (#9267), phospho-Akt (Ser473) (#4060), E-cadherin (#3195),
phospho-p70 S6 kinase (Thr389) (#9205), Total S6 ribosomal protein
(#2217), phospho-S6 (Ser235/236) (#4858), and Slug (#9585).

From Abcam: phospho-SGK1 (Ser422) (#ab55281) and Vimentin
(#ab92547).

From Millipore: N-cadherin (#04-1126).

RNA purification and expression analysis
Responsible investigator: RNA purification and expression analysis were
completed by LER.

Total RNA was extracted from homogenous portions of macrodissected
uncultured tumors using an RNeasy Mini kit (Qiagen) and eluted in the
presence of Rnase inhibitor (Promega). RNA was quantified and
prepared per the University of Vermont Cancer Center Microarray Facility
standards. Quality was assessed by the facility with an Agilent 2100
Bioanalyzer. Samples were hybridized to GeneChip Mouse Gene 1.0 ST
Arrays (Affymetrix).
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Analysis of lymph node metastases
Responsible investigator: Data collection and analysis performed by LER.

Lymph nodes (cervical, axillary, brachial, and inguinal) were formalinfixed, paraffin-embedded and sections were stained with hematoxylin
and eosin (H&E). Images of each lymph node were digitally captured
and manually analyzed using Adobe Photoshop Creative Suite 5.

Quantification of lung metastases
Responsible investigator: Method development, data collection and
analysis were performed by LER.

Lung lobes were individually separated and rinsed in PBS at room
temperature. Each lobe was mounted to a glass slide with Permount and
coverslip and allowed to dry for 24 hours. Low and high power
microscopic images were obtained with a Vectra microscope from
Cambridge Research & Instrumentation (CRi) and digitally captured with
inForm software. Each high power image was manually assessed for the
presence or absence of melanoma metastases. This method was
developed (by LER) to be able to assess metastases not visible under a
dissecting microscopic and to allow for a more rigorous assessment of
each lung lobe.
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Statistical analyses
Responsible investigator: Statistical analyses were completed by LER.

Prism statistical analysis software was used for all analyses. Kaplan-Meier
survival curves were constructed and significance was determined using
the Log-rank (Mantel-Cox) test. For comparison of pooled data with two
groups, unpaired t tests were used to determine significance.
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Results
LOSS OF E-CADHERIN IN THE BRAF/PTEN TUMOR MODEL
In order to assess the role of E-cadherin in melanoma progression and
metastasis, we first examined its loss in the context of the wellcharacterized Braf/Pten tumor model. This model, previously published in
Nature Genetics in 2009, utilizes the Tyrosinase-CreERT system and
engineered loxP sites in the genes for Braf and Pten (8). When 4hydroxytamoxifen (4-HT) is applied to the mouse, these genes are altered
specifically in melanocytes, resulting in activation of Braf and loss of Pten.
These genetic changes result in melanoma in 100% of mice that is lethal in
approximately 30-40 days with metastases to the lymph nodes and lungs.

Two different modes of tumor induction have been developed. The first,
henceforth referred to as perinatal induction, involves applying 4-HT
topically on days 3, 5, and 7 of life leading to systemic absorption and
genetic recombination in effectively all melanocytes on the mouse. The
second method of tumor induction, called local induction, requires a
small volume of 4-HT applied once to a small area of skin on the mouse,
leading to genetic recombination in just that local area. This method of
local induction allows for a single tumor nodule to grow. Per the
approved animal protocol utilized here, mice were euthanized when the
tumor reached 1 cm3 in size.
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Decreased Survival with Loss of E-cadherin
These two methods were utilized to assess tumor growth and
development in the context of loss of E-caderin. The comparison groups
focused on in this section are the Braf/Pten inducible mice versus
Braf/Pten mice with inducible, melanocyte-specific loss of E-cadherin
(Braf/Pten/Ecad model) (Figure 1). As shown here, comparisons with both
the perinatal induction (Figure 1A) and the local induction (Figure 1B)
show a quicker progression to lethality in the Braf/Pten/Ecad group
compared to the Braf/Pten group (p=0.024 [perinatal induction] and
p=0.043 [local induction]).
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Figure 1. Kaplan-Meier survival curves for Braf/Pten/Ecad cohorts vs.
Braf/Pten cohorts. (A) Perinatal induction protocol and (B) Local
induction protocol.
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No Difference in Gross Phenotype
By inspection, there are no gross differences in the melanomas formed in
the Braf/Pten/Ecad tumor model compared to the Braf/Pten tumor model
(Figure 2). In both cases, the mice become covered in darkly pigmented
confluent melanoma (perinatal induction) (Figure 2A), including over their
peri-oral skin (Figure 2B) and footpads (Figure 2C).
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Figure 2. Gross phenotype (perinatal induction) of representative mice.
(A) Whole mouse, (B) Peri-oral skin, and (C) Footpads.
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Metastasis to the Lymph Nodes and Lungs
The next important assessment was to determine the pattern of
metastases in the Braf/Pten/Ecad cohort compared to the Braf/Pten
cohort. In both cohorts, metastases to the lymph nodes were assessed
and quantified from perinatally induced mice (Figure 3). Both cohorts
showed clear metastases to the lymph nodes both macroscopically and
histologically (Figure 3A and 3B). When the area of lymph node involved
with melanoma was quantified from the hematoxylin and eosin (H&E)
slides, there was no difference in the amount of melanoma in each lymph
node (p=0.28) (Figure 3C).
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Figure 3. Metastases to the Lymph Nodes. Metastases to the lymph
nodes can be seen (A) macroscopically and (B) histologically, stained
by hematoxylin and eosin (H&E). (C) Quantification of the area of
lymph node involved with melanoma.
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Additionally, metastases to the lungs were assessed in the two perinatally
induced cohorts (Figure 4). The number of lung metastases was
quantified by a newly developed pressed lung technique. This technique
allowed for visualization of microscopic metastases that are not easily
detected by other means (Figure 4A). These metastases were quantified
per lobe of lung and there was no difference between the two cohorts
(p=0.39) (Figure 4B).
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Figure 4. Metastases to the Lungs. Entire lung lobes were digitally
captured under a light microscope and assessed for the presence of
metastases. (A) Representative lung metastasis. (B) Quantification of
lung metastases per lobe in each cohort.
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Assessment of mTOR Activity
While both cohorts were expected to show significant mTOR activity due
to the engineered loss of Pten, it was important to assess for any changes
in activity of either mTORC1 or mTORC2 with concomitant loss of Ecadherin. This goal was accomplished through western blotting of tumor
protein lysates from representative samples of the two cohorts (Figure 5).
Several downstream targets of mTOR were assessed. For mTORC1 activity,
levels of phospho-4E-BP1 (Thr 37/46) and phospho-S6 ribosomal protein
(Ser235/236) were assessed along with total levels of S6 ribosomal protein
for comparison (Figure 5A). These threonine and serine residues on 4E-BP1
and S6, respectively, are known targets of mTORC1 and thus serve as a
proxy for the level of mTORC1 activity in these tumors. For mTORC2
activity, levels of phospho-SGK1 (Ser422) and phosphor-Akt (Ser473) were
assessed along with total Akt levels (Figure 5B). These serine residues are
known targets for mTORC2 and thus correlate with mTORC2 activity. From
this data there are no clear differences in either mTORC1 or mTORC2
activity in the Braf/Pten/Ecad tumors compared to the Braf/Pten tumors.

44

A

Braf / Pten / Ecad

Braf / Pten

Mel Skin

Braf / Pten / Ecad

Braf / Pten

mTORC1 activity

Mel Skin

p-4E-BP1
p-S6
Total S6
Actin

B

p-Akt (S473)
Total Akt

mTORC2 activity

p-SGK1

Actin

Figure 5. Assessment of mTOR activity. Western blotting was performed
on Braf/Pten/Ecad and Braf/Pten tumor lysates as well as control skin
lysate (Skin) and melanocyte lysate (Mel). (A) mTORC1 activity was
assessed by probing for phospo-4E-BP1 (Thr37/46) and phospho-S6
ribosomal protein (Ser235/236), with total S6 ribosomal protein and actin
controls. (B) mTORC2 activity was assessed by probing for phosphoSGK1 (Ser422) and phospho-Akt (Ser473), with total Akt and actin
controls.
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Markers of EMT
Finally, loss of E-cadherin is predicted to allow for EMT to occur. To assess
for markers of EMT, RNA extracted from each of the tumor cohorts was
probed and quantified using a mouse gene microarray. This data was
mined for markers of EMT, and RNA expression levels of these markers for
the Braf/Pten/Ecad were compared to expression levels in the Braf/Pten
cohort (Table 1). These markers fell into two broad categories:
transcription factors and structural proteins. While several of the
transcription factors and structural proteins that are predicted to be
upregulated following an EMT were indeed upregulated (Slug, Twist2,
Zeb1, N-cadherin and Fibronectin), others were equally expressed in the
two tumor cohorts (Snail, Twist1, Zeb2, Hif1α and Vimentin). Notably, one
protein expected to decrease following an EMT (Claudin 1) was
significantly upregulated in the Braf/Pten/Ecad cohort.
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Transcription Factors
Gene

Protein

Sample 1

Sample 2

Snai1

Snail

1.2

1.1

Snai2

Slug

5.6

9.6

Twist1

Twist1

1.3

1.8

Twist2

Twist2

3.1

2.3

Zeb1

Zeb1

10.8

8.8

Zeb2

Zeb2

1.6

1.7

Hif1α

Hif1α

0.8

0.6

Structural Proteins
Cdh2

N-cadherin

4.9

8.6

Vim

Vimentin

1.2

1.3

Fn1

Fibronectin

4.4

5.4

Cldn1

Claudin 1

14.5

24.7

Table 1. Microarray RNA expression levels of markers of EMT.
Fold-change in expression of RNA transcipts within Braf/Pten/Ecad
tumors (Samples 1 and 2) relative to Braf/Pten tumors.
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A NOVEL MOUSE MODEL: BRAF ACTIVATION AND LOSS OF E-CADHERIN
While the Braf/Pten/Ecad melanoma model allowed for analysis of
metastasis and markers of EMT compared to the previously characterized
Braf/Pten model (8), it was important to evaluate E-cadherin loss in a
system with fewer genetic changes to assess for its role in melanoma
formation. With that goal in mind, cohorts of mice were generated with
the same inducible melanocyte-specific system using the perinatal
induction protocol. The cohorts generated included loss of E-cadherin
only (Ecad model), Braf activation and loss of E-cadherin (Braf/Ecad
model), and loss of E-cadherin and loss of Pten (Pten/Ecad model). From
the previously published study on the Braf/Pten model, we also have data
for a cohort with Braf activation only (Braf model), a cohort with Pten loss
only (Pten model) and of course the data from the Braf/Pten cohort (8).
Together, these cohorts represent all possible permutations of these three
genetic changes (except for the Braf/Pten/Ecad tumor model described
in the previous section).

Braf Activation with Loss of E-cadherin Leads to Melanoma Formation
The Kaplan-Meier survival curves for all of the above-mentioned cohorts
were generated and followed until death or at least 1.5 years (Figure 6).
Examining these cohorts led to the discovery that Braf activation in
combination with E-cadherin loss leads to melanoma formation in 100% of
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the mice with tumor death occurring after an average of 302 days
(range: 199 – 395 days) or approximately 10 months. This finding is in
striking contrast to the Braf/Pten tumor model, which has an average
lifespan of 40 days (Figure 1, perinatal induction). Mice with loss of Ecadherin only, loss of Pten only or Braf activation only show no tumor
formation for 1.5 or more years. Additionally, the Pten/Ecad model shows
no tumor formation for an average of 720 days (range: 641 – 884 days) or
approximately 2 years. The Braf/Ecad tumor model when compared to
the other tumor models individually (none of which develop tumors) is
statistically significant with p<0.0001 for all comparisons. Additionally, the
Braf/Ecad tumor model is statistically different from the Braf/Pten tumor
model (p<0.0001).
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Figure 6. Kaplan-Meier survival curves for Braf/Ecad cohorts vs. Braf,
Pten, Ecad and Pten/Ecad cohorts. There is a statistically significant
difference (p<0.0001) between the Braf/Ecad cohort and all other
cohorts shown here.
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Assessment of mTOR Activity and Markers of EMT
In order to assess the functional changes that occurred within the
Braf/Ecad tumor model, western blotting was performed to investigate
mTOR activity as well as markers of EMT (Figure 7). First, mTORC1 activity
was assessed by looking at downstream targets, including phospho-4E-BP1
(Thr 37/46), phospho-S6 ribosomal protein (Ser235/236), and phospho-p70
S6 kinase (Thr389) (Figure 7A). From this data, there is evidence of
mTORC1 activity in the Braf/Ecad tumors, though somewhat decreased
compared to the Braf/Pten tumors. While there is less phosphorylation of
S6 ribosomal protein in just one out of three Braf/Ecad tumors, there is
decreased phosphorylation of both p70 S6 kinase and 4E-BP1 in all
Braf/Ecad tumors compared to Braf/Pten tumors.

Next, mTORC2 activity was assessed by looking at levels of phospho-SGK1
(Ser422) and phospho-Akt (Ser473) (Figure 7B). Additional phosphorylation
sites on Akt (Thr450 and Thr308) were also examined (Figure 7B). These
three Akt phosphorylation sites (Thr308, Ser473, and Thr450) all correspond
to activation of Akt. While one of the Braf/Ecad tumors has elevated
levels of phospho-SGK1 (Ser422) suggesting the possibility of elevated
mTORC2 activity, this is not consistent across the other two Braf/Ecad
tumors nor is it consistent when looking at phospho-Akt (Ser473), another
marker of mTORC2 activity. By examining the three phospho-Akt blots,
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there is a trend toward decreased, though present, phosphorylation of
Akt in the Braf/Ecad tumors compared to the Braf/Pten tumors. This result
suggests that Akt is active in the Braf/Ecad tumors, but less so than in
Braf/Pten tumors.

Finally, it is important to investigate whether or not an EMT has occurred
within the Braf/Ecad tumors. To assess this, tumor lysates were probed for
E-cadherin, N-cadherin, Slug, and Vimentin (Figure 7C). If an EMT has
occurred, one would predict decreased or no E-cadherin, increased Ncadherin (termed “cadherin-switching” to explain the “switch” from Ecadherin to N-cadherin), increased Vimentin (an intermediate filament
found in mesenchymal cells) and increased Slug (a transcription factor
that downregulates expression of E-cadherin). In the Braf/Ecad tumor
lysates the first important aspect to note is that two of the lysates contain
E-cadherin. This finding is due to contamination of the tumor lysate from
overlying skin, which strongly expresses E-cadherin (as can clearly be seen
in the skin lysate control) and not due to expression of E-cadherin in the
tumors (which have been genetically-engineered to lack E-cadherin).
Looking at the other structural proteins (N-cadherin and Vimentin), both
the Braf/Ecad and Braf/Pten tumors express similar levels of these proteins.
Interestingly, differences are found when examining expression levels of
Slug. There are wide variations in expression level when looking at the
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three Braf/Ecad tumors, from none to slight to high, while the Braf/Pten
tumors consistently show moderate expression of Slug. The variation in
expression levels in the Braf/Ecad tumors is not entirely surprising, as these
tumors have a long latency period with a wide range, suggesting there
might be stochastic variation within these tumors. This observation is in
contrast to the Braf/Pten tumor model, which has a short latency period
for tumor development and thus, little variability in protein expression.

53

	
  

A

Skin

Braf / Ecad

Braf / Pten

Mel

Skin

Braf / Ecad

Braf / Pten

Mel

Skin

Braf / Ecad

Braf / Pten

mTORC1 activity

Mel

p-4E-BP1
p-p70 S6
p-S6
Total S6
Actin

p-SGK1
p-Akt (S473)
p-Akt (T450)
p-Akt (T308)
Total Akt
Actin

C

N-cadherin
Slug
Vimentin
Actin
See next page for figure legend.

Markers of EMT

E-cadherin

mTORC2 and Akt activity

B

54

See previous page for figure.
Figure 7. mTORC1/2 activity, Akt activity and markers of EMT. Western
blotting was performed on Braf/Ecad and Braf/Pten tumor lysates as
well as control skin lysate (Skin) and melanocyte lysate (Mel). (A)
mTORC1 activity was assessed by probing for phospo-4E-BP1 (Thr37/46),
phospho-p70 S6 kinase (Thr389) and phospho-S6 ribosomal protein
(Ser235/236), with total S6 ribosomal protein and actin controls. (B)
mTORC2 activity was assessed by probing for phospho-SGK1 (Ser422)
and phospho-Akt (Ser473). Akt activity was additionally assessed with
phospho-Akt (Thr450) and phospho-Akt (Thr308). Total Akt and actin
controls are shown. (C) Markers of EMT include E-cadherin, N-caderin,
Slug, and Vimentin, with an actin control.
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As was previously established by the Bosenberg lab (8), activation of Braf
alone in melanocytes does not lead to melanoma formation but does
lead to nevi formation in 100% of mice. To further understand the
formation of tumors in the Braf/Ecad cohort, immunohistochemistry (IHC)
was performed on Braf/Ecad tumors and compared to IHC performed on
Braf/Pten tumors as well as these Braf-activated nevi (Figure 8).
Braf/Ecad tumors were probed for E-cadherin (to definitively show the
genetically engineered loss) as well as Vimentin (Figure 8A). A
representative hematoxylin and eosin (H&E) slide of a Braf/Ecad tumor is
also shown. It is worth noting that the Braf/Ecad tumor contains no Ecadherin, as expected, but that the overlying epidermis shows clear,
strong E-cadherin staining. Vimentin is strongly expressed in the Braf/Ecad
tumor.

To further establish mTORC1 activity in the Braf/Ecad tumors, IHC was
performed with phospho-S6 ribosomal protein (Ser235/236) antibody
(Figure 8B). This conclusively shows that mTORC1 is active in the Braf/Ecad
tumors at a similar level to that of Braf/Pten tumors and significantly
increased from Braf nevi. Additionally, the intensity of
immunohistochemical staining for mTORC2 substrates, including phosphoAkt (Ser473) and phospho-SGK1 (Ser422), was moderate and essentially
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equal in Braf/Ecad tumors and Braf/Pten tumors and was greater than
that seen in Braf nevi (data not shown).
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Figure 8. Markers of EMT and mTORC1 activity in Braf/Ecad tumors.
Immunohistochemistry was performed on Braf/Ecad tumors, Braf/Pten
tumors and nevi from mice with Braf activation alone. (A) Braf/Ecad
tumors were stained with H&E and also probed with antibodies to Ecadherin and Vimentin. (B) Braf/Ecad tumors, Braf/Pten tumors and
Braf nevi were probed for phospho-S6 ribosomal protein (Ser235/236) (a
marker of mTORC1 activity).
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Microarray Analysis of EMT
Finally, RNA microarray analysis was used to assess for markers of EMT
within the Braf/Ecad tumors and compared to the Braf/Pten tumors (Table
2). As discussed previously, these markers fell into two broad categories:
transcription factors and structural proteins. While several of the
transcription factors and structural proteins that are predicted to be
upregulated following an EMT were indeed up-regulated (Slug, Zeb1, Ncadherin and Fibronectin), others were equally expressed in the two
tumor cohorts (Snail, Twist1, Twist2, Zeb2, Hif1α and Vimentin). Notably,
one protein expected to decrease following an EMT (Claudin 1) was
significantly upregulated in the Braf/Ecad cohort. These data are quite
similar to that seen the Braf/Pten/Ecad cohort (Table 1).
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Transcription Factors
Gene

Protein

Sample 1

Sample 2

Snai1

Snail

1.0

0.8

Snai2

Slug

14.9

12.4

Twist1

Twist1

1.2

2.4

Twist2

Twist2

0.9

1.2

Zeb1

Zeb1

12.8

11.5

Zeb2

Zeb2

1.5

1.6

Hif1α

Hif1α

0.4

0.6

Structural Proteins
Cdh2

N-cadherin

25.3

18.1

Vim

Vimentin

1.5

1.4

Fn1

Fibronectin

10.9

5.7

Cldn1

Claudin 1

49.5

10.5

Table 2. Microarray RNA expression levels of markers of EMT.
Fold-change in expression of RNA transcipts within Braf/Ecad tumors
(Samples 1 and 2) relative to Braf/Pten tumors.

	
  

60

Discussion
This work investigates the role of E-cadherin loss in melanoma formation
and metastasis and its role in EMT. Few investigators have assessed Ecadherin in such a controlled manner in an in vivo immunocompetent
model. Two primary models were assessed here, that of Braf/Pten/Ecad
and the newly discovered Braf/Ecad model, but other genetic contexts
utilizing this melanocyte-specific inducible loss of E-cadherin could also be
developed in future work.

Interestingly, in the Braf/Pten/Ecad tumor model one would have
predicted an increase in metastases with possible concomitant increase
in mortality. While the Braf/Pten/Ecad tumor model does show a
decreased lifespan compared to the Braf/Pten tumor model, there are no
clear phenotypic differences between the two models and there is no
change in the metastatic potential. This finding suggests that if loss of Ecadherin leads to increased metastasis, it is contingent on genetic
context. While it is not clear why there is a decreased lifespan in this
cohort, changes in mTORC1/2 do not account for any differences
between these two models. Future investigation into tumor growth rates
and other mechanistic changes may shed light on these questions.
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The discovery that Braf activation in combination with loss of E-cadherin
was sufficient to produce melanoma in 100% of mice is somewhat
surprising, but may have been predictable due to the suggested role of Ecadherin as a tumor suppressor and increasing evidence that loss of Ecadherin leads to activation of the PI3K/Akt pathway (19) (20) (21). This
relationship, however, is challenging to so clearly illustrate in
epidemiologic or in vitro studies but is readily apparent in the melanoma
tumor model developed here. Mechanistic studies investigating the
Braf/Ecad tumors reveal activation of Akt, as well as both mTORC1 and
mTORC2, supporting the idea that loss of E-cadherin leads to activation of
the PI3K/Akt pathway in an in vivo immunocompetent cancer model. As
shown previously with the Braf/Pten tumor model (8), Braf activation with
activation of the PI3K/Akt pathway (in this model due to loss of Pten) is
synergistic and sufficient for melanoma formation in 100% of mice. The
same mechanism appears to be important in the development of tumors
in the Braf/Ecad model, though stochastic changes are likely to also play
a significant role given the long latency period of tumor development.

Finally, it is important to address the question of whether or not E-cadherin
induces an EMT. There were some markers of EMT that were upregulated
in both the Braf/Pten/Ecad cohort and the Braf/Ecad cohort relative to
Braf/Pten tumors. However, RNA levels of other markers were unchanged.
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Importantly though, loss of E-cadherin did not lead to wildly enhanced
metastasis (in either genetic context), suggesting that while some events
characteristic of an EMT did occur (as shown by the microarray data),
these events were not sufficient for increased metastasis. In reality, there is
likely a hybrid state that occurs in vivo, in so far as both mesenchymal and
epithelial markers are expressed in the highly abnormal dysregulated
cancer cell.

Within the study of E-cadherin and tumor metastasis, some investigators
believe that release of β-catenin is the key downstream mechanism
leading to the molecular changes and metastatic potential of cells
lacking E-cadherin. While β-catenin was not directly addressed in this
study, it has been definitively addressed by Damsky et al. with a mouse
model also developed in the Bosenberg lab (44). In this study, β-catenin
was both stabilized and knocked-out in an inducible manner and specific
to melanocytes in the context of Braf activation and loss of Pten. The
model that included β-catenin stabilization, Braf activation and Pten loss
(Braf/Pten/β-cat-STA) showed a remarkable increase in the number of
metastases to the lungs as well as to the spleen and bowel. This
phenotype is in stark contrast to that of the Braf/Pten/Ecad and Braf/Ecad
models and supports the idea that the functional changes within the cells
of these tumors from loss of E-cadherin are not simply due to changes of
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expression of β-catenin. Additionally, the tumors formed in the
Braf/Pten/β-cat-STA tumor model, despite being highly metastatic,
actually showed an increased level of E-cadherin expression.

While the work completed here further enhances the understanding of
the role of E-cadherin in melanoma formation and metastasis, more work
will need to be done to further understand the complexities of tumor
formation and spread. While loss of E-cadherin can play a substantial role
in melanoma formation as shown in the Braf/Ecad tumor model, its role in
EMT and metastasis is more complex and likely highly dependent on
genetic context. The Braf/Pten/Ecad tumor model did not show an
increase in metastases and the Braf/Pten/β-cat-STA model (44) shows a
remarkable increase in metastases but also with increased E-cadherin
expression. Additional genetic combinations will need to be investigated
to further understand the role of E-cadherin in melanoma formation and
metastasis. With better understanding, new treatments will be developed
to help manage this devastating cancer.
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